| ［1］ |
中国医疗保健国际交流促进会营养与代谢管理分会，中国营养学会临床营养分会，中华医学会糖尿病学分会，等.中国超重/肥胖医学营养治疗指南（2021） ［J］.中国医学前沿杂志（电子版），2021，13（11）：1-55.
|
| ［2］ |
Wang Y，Zhao L，Gao L，et al.Health policy and public health implications of obesity in China ［J］.The Lancet Diabetes &Endocrinology，2021，9（7）：446-461.
|
| ［3］ |
Phelps NH，Singleton RK，Zhou B，et al.Worldwide trends in underweight and obesity from 1990 to 2022：a pooled analysis of 3663 population-representative studies with 222 million children，adolescents，and adults ［J］.The Lancet，2024，403（10431）：1027-1050.
|
| ［4］ |
Dong Z，Xu L，Liu H，et al.Comparative efficacy of five long-term weight loss drugs：quantitative information for medication guidelines［J］.Obes Rev，2017，18（12）：1377-1385.
|
| ［5］ |
Gadde KM，Atkins KD.The limits and challenges of antiobesity pharmacotherapy ［J］.Expert Opinion on Pharmacotherapy，2020，21（11）：1319-1328.
|
| ［6］ |
Proietto J.Medicines for long-term obesity management ［J］.Australian Prescriber，2022，45（2）：38-40.
|
| ［7］ |
Gabe MBN，Breitschaft A，Knop FK，et al.Effect of oral semaglutide on energy intake，appetite，control of eating and gastric emptying in adults living with obesity：A randomized controlled trial ［J］.Diabetes Obes Metab，2024，26（10）：4480-4489.
|
| ［8］ |
Drucker DJ.Mechanisms of action and therapeutic application of glucagon-like peptide-1 ［J］.Cell Metab，2018，27（4）：740-756.
|
| ［9］ |
Wilding JPH，Batterham RL，Calanna S，et al.Once-weekly semaglutide in adults with overweight or obesity ［J］.N Engl J Med，2021，384（11）：989-1002.
|
| ［10］ |
Targher G，Mantovani A，Byrne CD.Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease［J］.Lancet Gastroenterol Hepatol，2023，8（2）：179-191.
|
| ［11］ |
Miyawaki K，Yamada Y，Ban N，et al.Inhibition of gastric inhibitory polypeptide signaling prevents obesity ［J］.Nature Medicine，2002，8（7）：738-742.
|
| ［12］ |
Varol C，Zvibel I，Spektor L，et al.Long-acting glucose-dependent insulinotropic polypeptide ameliorates obesity-induced adipose tissue inflammation ［J］.J Immunol，2014，193（8）：4002-4009.
|
| ［13］ |
Samms RJ，Coghlan MP，Sloop KW.How may GIP enhance the therapeutic efficacy of GLP-1？ ［J］.Trends Endocrinol Metab，2020，31（6）：410-421.
|
| ［14］ |
Jastreboff AM，Aronne LJ，Ahmad NN，et al.Tirzepatide once weekly for the treatment of obesity ［J］.N Engl J Med，2022，387（3）：205-216.
|
| ［15］ |
Tall Bull S，Nuffer W，Trujillo JM.Tirzepatide：A novel，first-in-class，dual GIP/GLP-1 receptor agonist ［J］.Journal of Diabetes and its Complications，2022，36（12）：108332.
|
| ［16］ |
Gratsianskaya SE，Valieva ZS，Martynyuk TV.The achievements of the modern specific therapy of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension：focus on the stimulator of soluble guanylate cyclase riociguat ［J］.Ter Arkh，2020，92（9）：77-84.
|
| ［17］ |
Flores-Costa R，Alcaraz-Quiles J，Titos E，et al.The soluble guanylate cyclase stimulator IW-1973 prevents inflammation and fibrosis in experimental non-alcoholic steatohepatitis ［J］.Br J Pharmacol，2018，175（6）：953-967.
|
| ［18］ |
Bower RL，Hay DL.Amylin structure-function relationships and receptor pharmacology：implications for amylin mimetic drug development ［J］.Br J Pharmacol，2016，173（12）：1883-1898.
|
| ［19］ |
Liberini CG，Boyle CN，Cifani C，et al.Amylin receptor components and the leptin receptor are co-expressed in single rat area postrema neurons ［J］.Eur J Neurosci，2016，43（5）：653-661.
|
| ［20］ |
Ueda T，Ugawa S，Saishin Y，et al.Expression of receptor-activity modifying protein （RAMP） mRNAs in the mouse brain ［J］.Brain Res Mol Brain Res，2001，93（1）：36-45.
|
| ［21］ |
Ludvik B，Lell B，Hartter E，et al.Decrease of stimulated amylin release precedes impairment of insulin secretion in type II diabetes ［J］.Diabetes，1991，40（12）：1615-1619.
|
| ［22］ |
Boyle CN，Lutz TA，Le Foll C.Amylin - Its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity ［J］.Mol Metab，2018，8：203-210.
|
| ［23］ |
Furió-Novejarque C，Sala-Mira I，Díez JL，et al.A model of subcutaneous pramlintide pharmacokinetics and its effect on gastric emptying：Proof-of-concept based on populational data ［J］.Comput Methods Programs Biomed，2024，244：107968.
|
| ［24］ |
D'ascanio AM，Mullally JA，Frishman WH.Cagrilintide：A longacting amylin analog for the treatment of obesity ［J］.Cardiol Rev，2024，32（1）：83-90.
|
| ［25］ |
Goto Y，Nomura M，Tanaka K，et al.Genetic interactions between activin type IIB receptor and Smad2 genes in asymmetrical patterning of the thoracic organs and the development of pancreas islets ［J］.Dev Dyn，2007，236（10）：2865-2874.
|
| ［26］ |
Allen DL，Cleary AS，Speaker KJ，et al.Myostatin，activin receptor IIb，and follistatin-like-3 gene expression are altered in adipose tissue and skeletal muscle of obese mice ［J］.Am J Physiol Endocrinol Metab，2008，294（5）：E918-E27.
|
| ［27］ |
Nunn E，Jaiswal N，Gavin M，et al.Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism ［J］.Mol Metab，2024，80：101880.
|
| ［28］ |
Kaur M，Misra S.Bimagrumab：an investigational human monoclonal antibody against activin type II receptors for treating obesity ［J］.J Basic Clin Physiol Pharmacol，2024，35（6）：325-334.
|
| ［29］ |
Kumawat VS，Kaur G.Therapeutic potential of cannabinoid receptor 2 in the treatment of diabetes mellitus and its complications ［J］.Eur J Pharmacol，2019，862：172628.
|
| ［30］ |
Rohbeck E，Eckel J，Romacho T.Cannabinoid receptors in metabolic regulation and diabetes ［J］.Physiology （Bethesda），2021，36（2）：102-113.
|
| ［31］ |
Lingvay I，Brown-Frandsen K，Colhoun HM，et al.Semaglutide for cardiovascular event reduction in people with overweight or obesity：SELECT study baseline characteristics ［J］.Obesity，2022，31（1）：111-122.
|
| ［32］ |
Knop FK，Aroda VR，Do Vale RD，et al.Oral semaglutide 50 mg taken once per day in adults with overweight or obesity （OASIS 1）：a randomised，double-blind，placebo-controlled，phase 3 trial ［J］.Lancet，2023，402（10403）：705-719.
|
| ［33］ |
Weghuber D，Barrett T，Barrientos-Pérez M，et al.Once-weekly semaglutide in adolescents with obesity ［J］.N Engl J Med，2022，387（24）：2245-2257.
|
| ［34］ |
Kosiborod MN，Petrie MC，Borlaug BA，et al.Semaglutide in patients with obesity-related heart failure and type 2 diabetes ［J］.New England Journal of Medicine，2024，390（15）：1394-1407.
|
| ［35］ |
Wilding JPH，Batterham RL，Davies M，et al.Weight regain and cardiometabolic effects after withdrawal of semaglutide：The STEP 1 trial extension ［J］.Diabetes，Obesity and Metabolism，2022，24（8）：1553-1564.
|
| ［36］ |
Ryan DH，Lingvay I，Deanfield J，et al.Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial ［J］.Nature Medicine，2024，30（7）：2049-2057.
|
| ［37］ |
Kosiborod MN，Abildstrøm SZ，Borlaug BA，et al.Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity ［J］.New England Journal of Medicine，2023，389（12）：1069-1084.
|
| ［38］ |
Gao L，Huang H，Zhang L，et al.Comparison of Beinaglutide Versus Metformin for Weight Loss in Overweight and Obese Non-diabetic Patients ［J］.Exp Clin Endocrinol Diabetes，2022，130（6）：358-367.
|
| ［39］ |
Chen K，Chen L，Shan Z，et al.Beinaglutide for weight management in Chinese individuals with overweight or obesity：A phase 3 randomized controlled clinical study ［J］.Diabetes，Obesity and Metabolism，2023，26（2）：690-698.
|
| ［40］ |
Zimmermann T，Thomas L，Baader-Pagler T，et al.BI 456906：Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy ［J］.Mol Metab，2022，66：101633.
|
| ［41］ |
Le Roux CW，Steen O，Lucas KJ，et al.Glucagon and GLP-1 receptor dual agonist survodutide for obesity：a randomised，double-blind，placebo-controlled，dose-finding phase 2 trial ［J］.The Lancet Diabetes& Endocrinology，2024，12（3）：162-173.
|
| ［42］ |
Ji L，Jiang H，An P，et al.IBI362 （LY3305677），a weekly-dose GLP-1 and glucagon receptor dual agonist，in Chinese adults with overweight or obesity：A randomised，placebo-controlled，multiple ascending dose phase 1b study ［J］.EClinicalMedicine，2021，39：101088.
|
| ［43］ |
Ji L，Jiang H，Cheng Z，et al.A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity ［J］.Nature Communications，2023，14（1）：8289.
|
| ［44］ |
Ji L，Gao L，Jiang H，et al.Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide （IBI362） 9 mg and 10 mg in Chinese adults with overweight or obesity：A randomised，placebo-controlled，multiple-ascending-dose phase 1b trial ［J］.EClinicalMedicine，2022，54：101691.
|
| ［45］ |
Pratt E，Ma X，Liu R，et al.Orforglipron （LY3502970），a novel，oral non-peptide glucagon-like peptide-1 receptor agonist：A Phase 1a，blinded，placebo-controlled，randomized，single- and multipleascending-dose study in healthy participants ［J］.Diabetes Obes Metab，2023，25（9）：2634-2641.
|
| ［46］ |
Wharton S，Blevins T，Connery L，et al.Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity ［J］.N Engl J Med，2023，389（10）：877-888.
|
| ［47］ |
Lupianez-Merly C，Dilmaghani S，Vosoughi K，et al.Review article：Pharmacologic management of obesity - updates on approved medications，indications and risks ［J］.Alimentary Pharmacology &Therapeutics，2024，59（4）：475-491.
|
| ［48］ |
Jastreboff AM，Kaplan LM，Frías JP，et al.Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial ［J］.New England Journal of Medicine，2023，389（6）：514-526.
|
| ［49］ |
Enebo LB，Berthelsen KK，Kankam M，et al.Safety，tolerability，pharmacokinetics，and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management：a randomised，controlled，phase 1b trial［J］.Lancet，2021，397（10286）：1736-1748.
|
| ［50］ |
Li H，Yu G，Huang Q，et al.Efficacy and safety of GLP-1RAs for people with obesity：A systematic review based on RCT and Bayesian network meta-analysis ［J］.Biomed Pharmacother，2024，171：116150.
|
| ［51］ |
Jastreboff AM，Kaplan LM，Frías JP，et al.triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial ［J］.N Engl J Med，2023，389（6）：514-526.
|
| ［52］ |
Grilo CM，Lydecker JA，Jastreboff AM，et al.Naltrexone/bupropion for binge-eating disorder：A randomized，double-blind，placebocontrolled trial ［J］.Obesity （Silver Spring），2023，31（11）：2762-2773.
|
| ［53］ |
Onakpoya IJ，Lee JJ，Mahtani KR，et al.Naltrexone-bupropion（Mysimba） in management of obesity：A systematic review and metaanalysis of unpublished clinical study reports ［J］.Br J Clin Pharmacol，2020，86（4）：646-667.
|
| ［54］ |
Greenway FL，Fujioka K，Plodkowski RA，et al.Effect of naltrexone plus bupropion on weight loss in overweight and obese adults （COR-I）：a multicentre，randomised，double-blind，placebo-controlled，phase 3 trial ［J］.Lancet，2010，376（9741）：595-605.
|
| ［55］ |
Thomas B，Lindblad AJ，Luu T，et al.Naltrexone-bupropion for weight loss ［J］.Can Fam Physician，2023，69（9）：627.
|
| ［56］ |
中华医学会内分泌学分会.肥胖患者的长期体重管理及药物临床应用指南（2024版） ［J］.中华内分泌代谢杂志，2024，40（7）：545-564.
|